Jul. 20 at 6:17 PM
$SCNX [5-10X Valuation] Go onto GoodRx (below), and search for Arbli - you will see it priced in every domestic (US) market across every major pharmacy chain, which means that it is commercially available. A quick DCF (2025-2041) of SCNX assuming a
$350-500Mils Losartan Market today (2025), 2.5% CAGR, 16% Penetration of Liquid formulation (Arbli, exclusivity to 2041), 10-15% Net Margin, 10% WACC and 1:1 NM to Unlevered FCF (all reasonable if not conservative assumptions), you will see a valuation here of
$240-300Mils. This is just for Arbli - it assumes absolutely nothing for Rezenopy (also shown on GoodRx, but not yet with pricing/availability), or any other drugs currently in the Corporate pipeline. The Company is presently valued at
$27MILS. 5-10X (IMO) from this level - and this is the math to prove it.
Compare the valuations:
$VTYX:
$225MILS
$IMRX:
$149MILS
$DRUG:
$189MILS
$RGC:
$7.2Bils
https://www.goodrx.com/arbli?srsltid=AfmBOoqklh6SZAag6dP2XoL_iyutunHKw5yA7S-un_BopP1bV9Tp3Xdc
